Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of $328.13 billion. The enterprise value is $356.24 billion.
| Market Cap | 328.13B |
| Enterprise Value | 356.24B |
Important Dates
The last earnings date was Thursday, April 25, 2024, before market open.
| Earnings Date | Apr 25, 2024 |
| Ex-Dividend Date | Mar 14, 2024 |
Share Statistics
Merck & Co. has 2.53 billion shares outstanding. The number of shares has decreased by -0.27% in one year.
| Shares Outstanding | 2.53B |
| Shares Change (YoY) | -0.27% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 78.61% |
| Float | 2.53B |
Valuation Ratios
The trailing PE ratio is 143.94 and the forward PE ratio is 15.01. Merck & Co.'s PEG ratio is 0.10.
| PE Ratio | 143.94 |
| Forward PE | 15.01 |
| PS Ratio | 5.34 |
| Forward PS | 5.08 |
| PB Ratio | 8.12 |
| P/FCF Ratio | 29.68 |
| PEG Ratio | 0.10 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 39.72, with an EV/FCF ratio of 32.27.
| EV / Earnings | 154.49 |
| EV / Sales | 5.80 |
| EV / EBITDA | 39.72 |
| EV / EBIT | 69.81 |
| EV / FCF | 32.27 |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.85.
| Current Ratio | 1.25 |
| Quick Ratio | 0.68 |
| Debt / Equity | 0.85 |
| Debt / EBITDA | 3.82 |
| Debt / FCF | 3.10 |
| Interest Coverage | 4.23 |
Financial Efficiency
Return on equity (ROE) is 5.80% and return on invested capital (ROIC) is 3.37%.
| Return on Equity (ROE) | 5.80% |
| Return on Assets (ROA) | 2.20% |
| Return on Capital (ROIC) | 3.37% |
| Revenue Per Employee | $852,806 |
| Profits Per Employee | $32,028 |
| Employee Count | 72,000 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.54 |
Taxes
In the past 12 months, Merck & Co. has paid $1.59 billion in taxes.
| Income Tax | 1.59B |
| Effective Tax Rate | 40.81% |
Stock Price Statistics
The stock price has increased by +9.43% in the last 52 weeks. The beta is 0.40, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (1Y) | 0.40 |
| 52-Week Price Change | +9.43% |
| 50-Day Moving Average | 126.40 |
| 200-Day Moving Average | 113.98 |
| Relative Strength Index (RSI) | 57.34 |
| Average Volume (30 Days) | 8,211,647 |
Short Selling Information
The latest short interest is 20.43 million, so 0.81% of the outstanding shares have been sold short.
| Short Interest | 20.43M |
| Short Previous Month | 23.16M |
| Short % of Shares Out | 0.81% |
| Short % of Float | 0.81% |
| Short Ratio (days to cover) | 2.11 |
Income Statement
In the last 12 months, Merck & Co. had revenue of $61.40 billion and earned $2.31 billion in profits. Earnings per share was $0.90.
| Revenue | 61.40B |
| Gross Profit | 45.66B |
| Operating Income | 4.25B |
| Pretax Income | 3.90B |
| Net Income | 2.31B |
| EBITDA | 8.97B |
| EBIT | 5.10B |
| Earnings Per Share (EPS) | $0.90 |
Balance Sheet
The company has $5.62 billion in cash and $34.22 billion in debt, giving a net cash position of -$28.60 billion or -$11.29 per share.
| Cash & Cash Equivalents | 5.62B |
| Total Debt | 34.22B |
| Net Cash | -28.60B |
| Net Cash Per Share | -$11.29 |
| Equity / Book Value | 40.36B |
| Book Value Per Share | 15.94 |
| Working Capital | 6.35B |
Cash Flow
In the last 12 months, operating cash flow was $14.76 billion and capital expenditures -$3.72 billion, giving a free cash flow of $11.04 billion.
| Operating Cash Flow | 14.76B |
| Capital Expenditures | -3.72B |
| Free Cash Flow | 11.04B |
| FCF Per Share | $4.36 |
Margins
Gross margin is 74.37%, with operating and profit margins of 6.92% and 3.76%.
| Gross Margin | 74.37% |
| Operating Margin | 6.92% |
| Pretax Margin | 6.35% |
| Profit Margin | 3.76% |
| EBITDA Margin | 14.61% |
| EBIT Margin | 8.31% |
| FCF Margin | 17.98% |
Dividends & Yields
This stock pays an annual dividend of $3.08, which amounts to a dividend yield of 2.38%.
| Dividend Per Share | $3.08 |
| Dividend Yield | 2.38% |
| Dividend Growth (YoY) | 5.63% |
| Years of Dividend Growth | 14 |
| Payout Ratio | 342.22% |
| Buyback Yield | 0.27% |
| Shareholder Yield | 2.66% |
| Earnings Yield | 0.70% |
| FCF Yield | 3.37% |
Analyst Forecast
The average price target for Merck & Co. is $131.15, which is 1.24% higher than the current price. The consensus rating is "Buy".
| Price Target | $131.15 |
| Price Target Difference | 1.24% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 4.62% |
| EPS Growth Forecast (5Y) | 142.20% |
Stock Splits
The last stock split was on June 3, 2021. It was a forward split with a ratio of 1048:1000.
| Last Split Date | Jun 3, 2021 |
| Split Type | Forward |
| Split Ratio | 1048:1000 |
Scores
Merck & Co. has an Altman Z-Score of 4.57 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.57 |
| Piotroski F-Score | 7 |